Last reviewed · How we verify
Vitamin-K antagonist at INR 2-3
Vitamin-K antagonist at INR 2-3 is a Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development. Also known as: Warfarin.
At a glance
| Generic name | Vitamin-K antagonist at INR 2-3 |
|---|---|
| Also known as | Warfarin |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Oral Anticoagulation in Haemodialysis Patients (PHASE4)
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters (PHASE3)
- Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) (PHASE3)
- DOAC Versus VKA After Cardiac Surgery (PHASE2)
- Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus (PHASE3)
- DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT. (PHASE3)
- Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin-K antagonist at INR 2-3 CI brief — competitive landscape report
- Vitamin-K antagonist at INR 2-3 updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Vitamin-K antagonist at INR 2-3
What is Vitamin-K antagonist at INR 2-3?
Vitamin-K antagonist at INR 2-3 is a Small molecule drug developed by AstraZeneca.
Who makes Vitamin-K antagonist at INR 2-3?
Vitamin-K antagonist at INR 2-3 is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
Is Vitamin-K antagonist at INR 2-3 also known as anything else?
Vitamin-K antagonist at INR 2-3 is also known as Warfarin.
What development phase is Vitamin-K antagonist at INR 2-3 in?
Vitamin-K antagonist at INR 2-3 is in Phase 2.
Related
- Manufacturer: AstraZeneca — full pipeline
- Also known as: Warfarin
- Compare: Vitamin-K antagonist at INR 2-3 vs similar drugs
- Pricing: Vitamin-K antagonist at INR 2-3 cost, discount & access